title: Bromophenacyl bromide, a phospholipase A2 inhibitor attenuates chemically induced gastroduodenal ulcers in rats.
abstract: OBJECTIVE
  To study the effect of bromophenacyl bromide (BPB), a phospholipase A2 inhibitor on gastric secretion and to protect chemically induced gastric and duodenal ulcers in rats.
  
  
  METHODS
  Acid secretion studies were undertaken in pylorus-ligated rats with BPB treatment (0, 5, 15 and 45 mg/kg). Gastric and duodenal lesions in the rats were induced by ethanol and cysteamine respectively. The levels of gastric wall mucus, nonprotein sulfhydryls (NP-SH) and myeloperoxidase (MPO) were also measured in the glandular stomach of rats following ethanol induced gastric lesions.
  
  
  RESULTS
  BPB produced a dose-dependent inhibition of gastric acid secretion and acidity in rats. Pretreatment with BPB significantly attenuated the formation of ethanol induced gastric lesion. BPB also protected intestinal mucosa against cysteamine-induced duodenal ulcers. The antiulcer activity of BPB was associated with significant inhibition of ethanol-induced depletion of gastric wall mucus, NP-SH and MPO. These findings pointed towards the mediation of sulfhydryls in BPB induced gastrointestinal cytoprotection.
  
  
  CONCLUSIONS
  BPB possesses significant antiulcer and cytoprotective activity against experimentally induced gastroduodenal lesions.
authors.affiliation: Frcpath, Frsc Senior Consultant and Director of Research, Armed Forces Hospital, Po Box 7897 (W-912), Riyadh 11159, Kingdom of Saudi Arabia. rkh_research@yahoo.com
authors.forename: Mohammad
authors.initials: M
authors.lastname: Tariq
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Elfaki
authors.forename: Haseeb-Ahmad
authors.initials: HA
authors.lastname: Khan
authors.forename: Mohammad
authors.initials: M
authors.lastname: Arshaduddin
authors.forename: Samia
authors.initials: S
authors.lastname: Sobki
authors.forename: Meshal
authors.initials: M
authors.lastname: Al Moutaery
mesh_terms: D000098:Acetophenones / Q000494:pharmacology*; D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D003543:Cysteamine; D000431:Ethanol; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D010437:Peptic Ulcer / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D009195:Peroxidase / Q000378:metabolism; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D054467:Phospholipases A2; D051381:Rats; D017208:Rats, Wistar; D013438:Sulfhydryl Compounds / Q000378:metabolism
chemical_list: D000098:Acetophenones; D000897:Anti-Ulcer Agents; D013438:Sulfhydryl Compounds; D000431:Ethanol; D003543:Cysteamine; D009195:Peroxidase; D010741:Phospholipases A; D054467:Phospholipases A2; C006821:4-bromophenacyl bromide